Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rani Therapeutics Holdings Inc (RANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: RANI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.97% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.61M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 4 | Beta -0.02 | 52 Weeks Range 0.39 - 3.34 | Updated Date 09/16/2025 |
52 Weeks Range 0.39 - 3.34 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3796.75% |
Management Effectiveness
Return on Assets (TTM) -93.94% | Return on Equity (TTM) -1187.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35330954 | Price to Sales(TTM) 29.68 |
Enterprise Value 35330954 | Price to Sales(TTM) 29.68 | ||
Enterprise Value to Revenue 29.44 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 47898200 | Shares Floating 33616892 |
Shares Outstanding 47898200 | Shares Floating 33616892 | ||
Percent Insiders 19.56 | Percent Institutions 17.01 |
Upturn AI SWOT
Rani Therapeutics Holdings Inc
Company Overview
History and Background
Rani Therapeutics Holdings, Inc. was founded in 2012. It is a biotherapeutics company focused on developing and commercializing orally administered biologics.
Core Business Areas
- RaniPillu00ae Capsule Technology: Developing and refining a novel drug delivery platform that enables oral administration of large molecules (biologics) that are typically administered via injection.
Leadership and Structure
Mir Imran is the Chairman and CEO. The company has a standard organizational structure with departments focused on R&D, manufacturing, and business development.
Top Products and Market Share
Key Offerings
- RaniPillu00ae Capsule: An orally administered capsule designed to deliver biologic drugs. Currently in clinical trials. Competitors include companies developing alternative drug delivery systems for biologics, such as subcutaneous injections (Amgen, Novo Nordisk) and other oral delivery platforms.
Market Dynamics
Industry Overview
The pharmaceutical industry is increasingly focused on biologics, but oral delivery remains a significant challenge. The market is competitive with companies seeking innovative drug delivery solutions.
Positioning
Rani Therapeutics aims to disrupt the biologics market by enabling oral delivery, potentially improving patient convenience and compliance. Their competitive advantage lies in their RaniPillu00ae platform.
Total Addressable Market (TAM)
The TAM for injectable biologics is substantial (hundreds of billions of dollars). Rani is positioned to capture a portion of this TAM by converting injectable biologics to oral formulations.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology
- Potential for improved patient compliance
- Strong intellectual property portfolio
Weaknesses
- Technology is still in clinical development
- High development costs
- Regulatory hurdles
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increased adoption of oral biologics
Threats
- Clinical trial failures
- Competition from existing delivery methods
- Regulatory delays
- Patent infringement
Competitors and Market Share
Key Competitors
- VTVT
- SAVA
- AZN
Competitive Landscape
Rani's key advantage is its unique oral delivery technology for biologics. Disadvantages include the risks inherent in clinical development and competition from established injection-based therapies and other novel oral delivery platforms.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D milestones and funding achievements.
Future Projections: Future growth depends on the success of clinical trials and securing partnerships with pharmaceutical companies. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing clinical trials of RaniPillu00ae formulations of various biologics.
Summary
Rani Therapeutics is a biotherapeutics company with a novel oral drug delivery platform. Its success hinges on the outcome of clinical trials and partnerships. The company faces risks associated with drug development, regulatory hurdles, and competition. However, if the RaniPillu00ae proves successful, it could significantly disrupt the biologics market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rani Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-07-30 | CEO & Director Mr. Talat Imran | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.ranitherapeutics.com |
Full time employees 105 | Website https://www.ranitherapeutics.com | ||
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.